巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Neoleukin Therapeutics

NLTX
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Neoleukin Therapeutics - 延遲價格・最後更新於 20/01 22:00
最高位
--
最低位
--
開市價
--
前收市價
3.380
成交量(千)
--
成交額(百萬)
--
買入
--
賣出
--
每手股數
--
市值(百萬)
143.41
市盈率
--
息率
--
差價
--
52週高低
15.890 - 3.360
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Neoleukin Therapeutics
證券代碼
NLTX.US
所屬板塊
Drug Manufacturers - Specialty & Generic
公司業務
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
發行量
42425071
公司總部
188 East Blaine Street, Suite 450
公司網址
https://www.neoleukin.com
公司電郵
investors@neoleukin.com
公司電話
+1 866 245-0312
暫無內容

關於

Neoleukin Therapeutics(NLTX.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
詳細公司背景可參考: https://www.neoleukin.com